Prolaris® – A prognostic test for prostate cancer.

Prolaris®, a novel prognostic test developed by Myriad Genetic Laboratories, directly measures tumor cell growth characteristics for stratifying the risk of disease progression in prostate cancer patients. Prolaris is a risk stratification tool for patients with prostate cancer. It can enable you to better define a management strategy for your patients with prostate cancer, enhancing their quality of life without jeopardizing their life expectancy.

About Prolaris
Prolaris provides a quantitative measure of the RNA expression levels of multiple genes related to the progression of tumor cell division. The 46-gene expression signature includes cell cycle progression genes selected based upon correlation with prostate tumor cell proliferation: low gene expression is associated with a low risk of disease progression and high gene expression is associated with disease progression.

Prolaris can identify low or intermediate-risk patients who may be candidates for surveillance as well as patients who may be potentially at higher risk and benefit from closer monitoring or additional therapy. Prolaris has been proven to predict prostate cancer-specific disease progression in numerous published clinical trials.

Published Papers
Prognostic Utility of the Cell Cycle Progression Score Generated from Biopsy in Men Treated with Prostatectomy

Cell cycle progression score and treatment decisions in prostate cancer: results from an ongoing registry

Prognostic utility of CCP score in men with prostate cancer after primary external beam radiation therapy

Validation of a Cell-Cycle Progression Gene Panel to Improve Risk Stratification in a Contemporary Prostatectomy Cohort.

Prognostic value of a cell cycle progression signature for prostate cancer death on conservatively managed needle biopsy cohort.

Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study.
Posters

Evaluation of the Economic Impact of the CCP Assay in Localized Prostate Cancer

Impact of CCP Test on Personalizing Treatment Decisions: Results From a Large Prospective Registry of Newly Diagnosed Prostate Cancer Patients

Validation of an Active Surveillance Threshold for the CCP Score In Conservatively Managed Men With Localized Prostate Cancer

Predicting Radical Prostatectomy Outcome Among Men Who Upgrade from Clinical Gleason 6 to Pathologic Gleason 7

Predicting Radical Prostatectomy Outcome Among Men Who Upgrade from Clinical Gleason 6 to Pathologic Gleason 7

Prognostic Utility of The Cell Cycle Progression (CCP) Score Generated From Needle Biopsy in Men Treated With Prostatectomy

Cell Cycle Progression-Combined Risk Score Stratifies Prostate Cancer Risk and Significantly Modifies Treatment Decisions in Prostate Cancer

Cell Cycle Progression (CCP) Score Significantly Modifies Treatment Decisions in Prostate Cancer: Results of an Ongoing Registry Trial

Prognostic utility of the cell cycle progression (CCP) score generated from needle biopsy in men treated with prostatectomy

CCP score stratifies risk for prostate cancer patients at biopsy: Initial commercial results

Clinical utility of CCP test in facilitating prostate cancer treatment decisions
Neal Shore, Raoul Concepcion, Daniel Saltzstein, M. Scott Lucia, Arletta van Breda, Kirstin M. Roundy, William Welbourn, and Michael Brawer. Society of Urologic Oncology Annual Meeting, December 4-6, 2013, Bethesda, MD.

The CCP Score: A Novel Genetic Test for Prostate Cancer

Prognostic utility of CCP Score in men with prostate cancer after primary EBRT
Value of cell cycle progression score to predict biochemical recurrence and post-surgical pathology

Evidence for cell cycle proliferation field effect in prostate cancer
David M. Berman, William Welbourn, Julia Reid, Elizabeth Humphries, Misop Han, Jerry Lanchbury, Alexander Gutin, Steven Stone, and Filipe Carvalho. European Association of Urology (EAU) Annual Congress, March 15-19, 2013, Milan, Italy.

Prolaris CCP score stratifies risk for prostate cancer patients at biopsy

Development and validation of a multivariate model combining cell cycle progression score with CAPRA to predict prostate cancer mortality in a conservatively managed cohort.
Michael Brawer, Mathew Cooperberg, Stephen Freedland, Gregory Swanson, Steven Stone, Julia Reid, Alexander Gutin, Peter Carroll, and Jack Cuzick. Society of Urologic Oncology (SUO) Annual Meeting, November 28-30, 2012, Bethesda, MD.

Validation of a panel of cell-cycle progression genes for improved risk-stratification in a contemporary radical prostatectomy cohort.

CCP score is a strong predictor of outcome in several prostate cancer cohorts.
Steven Stone, Jack Cuzick, Daniel Berney, Julia Reid, David Mesher, Gabrielle Fisher, Jerry Lanchbury, Alexander Gutin, Gregory Swanson, and on behalf of the Transatlantic Prostate Group. Society of Urologic Oncology (SUO) Annual Meeting, December 2011, Bethesda, MD..

Presentations

Evaluation Of The CCP Score As An Indicator Of Biochemical Recurrence In A Community Cohort

Cell Cycle Progression (CCP) Score Significantly Predicts PSA Failure After EBRT

Prolaris: A Novel Genetic Test for Prostate Cancer Prognosis

Cell cycle progression genes differentiate indolent from aggressive prostate cancer
Steven Stone, Jack Cuzick, Dan Berney, Julia Reid, David Mesher, Gabrielle Fisher, Jerry Lanchbury, Alexander Gutin, Greg Swanson, and on behalf of the Transatlantic Prostate Group. American Association for Cancer Research (AACR) – Advances in Prostate Cancer Research, February 6-9, 2012, Orlando, FL.

Prognostic value of a cell cycle expression profile score among men with conservatively treated localized prostate cancer
Jack Cuzick, Gabrielle Fisher, Dan Berney, David Mesher, Henrik Møller, Jerry Lanchbury, Alexander Gutin, Steven Stone; European Society of Medical Oncology (ESMO) Congress, Milan, Italy, October 2010.